June 2020 Volume 16, Issue 6

Volume 16, Issue 6 | June 2020

June 2020

In this Issue

Clinical Trials

Drug Discovery News Placeholder Image

Well-tolerated tumor drug

Antibody therapeutic from Compugen demonstrates no dose-limiting toxicities
Drug Discovery News Placeholder Image

Optimal OPTICs

ADVM-022 demonstrates efficacy, durability in OPTIC trial in wet AMD
Drug Discovery News Placeholder Image

More skin in the game

Libtayo shows promise for a second indication
Drug Discovery News Placeholder Image

Usher update

ProQR offers upbeat interim analysis in Phase 1/2 trial of QR-421a for Usher Syndrome
Drug Discovery News Placeholder Image

Investigating an IL-6 antibody

An update on Sanofi and Regeneron’s Kevzara trial in hospitalized COVID-19 patients

Diagnostics

Drug Discovery News Placeholder Image

A better test for COVID-19

Digital PCR solution cuts down on false negatives, may help in clinical trials
Drug Discovery News Placeholder Image

Against antibiotic resistance

Selux Diagnostics receives additional 9.6 million for rapid AST platform
Drug Discovery News Placeholder Image

Putting the ‘AI’ in diagnostics

A look at the growing trend of integrating artificial intelligence and machine learning with diagnostics

Business & Government Policy

Drug Discovery News Placeholder Image

Broadening its footprint in biotech

Germany’s Sartorius acquires selected assets of Danaher Life Sciences
Drug Discovery News Placeholder Image

On the cutting edge

A roundup of instrumentation, software and other tools and technology news
Drug Discovery News Placeholder Image

Q&A: The challenges of a vaccine for COVID-19

DDN takes some time to speak with Amélie Boulais, vaccine platform marketing manager at Sartorius Stedim Biotech

Research & Development

Drug Discovery News Placeholder Image

Meaningful biomarkers

Precision medicine analyses show potential for Alzheimer’s drug
Drug Discovery News Placeholder Image

AUM launches Knockdown Coronavirus

RNA could be the kryptonite to defeat COVID-19
Drug Discovery News Placeholder Image

Building a biobank

Biogen, Broad Institute and Partners HealthCare create consortium for COVID-19 efforts
Drug Discovery News Placeholder Image

Timing is everything

Suppression of immune system may be key to reducing COVID-19 severity

Discovery

Drug Discovery News Placeholder Image

Complementary cancer collaboration

Exscientia and SRI combine strengths for oncology drug discovery
Drug Discovery News Placeholder Image

Relying on RNAi

Vir and Alnylam identify RNAi development candidate targeting SARS-CoV-2
Drug Discovery News Placeholder Image

Arrakis partners with Roche

Collaboration will use RNA-targeted small-molecule discovery platform for multiple targets
Drug Discovery News Placeholder Image

Further success in malaria initiative

Optibrium and Intellegens report in-vitro validation of in-silico-generated compound
Drug Discovery News Placeholder Image

Know your enemy

Team uses knowledge of how SARS-CoV-2 infects cells to identify drugs that could combat it
Drug Discovery News Placeholder Image

Managing macrolactones

New database could aid large-molecule drug discovery and research

Contract Services

Drug Discovery News Placeholder Image

A strong complement in China

Reaction Biology, PharmaCore Labs strike up collaboration agreement
Drug Discovery News Placeholder Image

Making a deal on ADCs

Trio Pharmaceuticals and Ajinomoto enter into development collaboration

Preclinical

Drug Discovery News Placeholder Image

Data recommend RECCE 327

Synthetic antibiotic shows efficacy against priority antibiotic-resistant pathogen
Drug Discovery News Placeholder Image

An autoimmune option

Immutep and Batavia Biosciences reach LAG-3 immunotherapy milestone
Drug Discovery News Placeholder Image

Negative Data Prize is a positive?

Global Preclinical Data Forum says sharing negative science results is key to neuroscience progress

Feature

Drug Discovery News Placeholder Image

Focus Feature on Cancer Research News

Recent happenings on the R&D front to better understand cancer and create oncology therapeutics

Commentary

Drug Discovery News Placeholder Image

Testing, testing, testing...1,2,3,4

Diagnostic testing is hotter news right now with COVID than perhaps ever before, but what does it all mean?
Drug Discovery News Placeholder Image

Guest Commentary: Accelerating the pace of pharma innovation at a molecular level

Innovation isn’t just measured in the number of approvals, and looking at NMEs might be a better gauge of the ways in which drug discovery is currently thriving

Special Reports

Drug Discovery News Placeholder Image

Special Report on Cancer: Anticipating antibodies

Digging deeper into repertoires means tapping into Plan B (cell)

Editor's Focus

Cancer, COVID

Editor’s Focus: Cancer, COVID and change

Change is the name of the game in our understanding of cancer, the effect of COVID and the future of DDN magazine
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist wearing gloves handles a pipette over a petri dish and a color-coded microplate in a laboratory setting.

The unsung tools behind analytical testing success

Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
A 3D rendering of motor neurons lit up with blue, purple, orange, and green coloring showing synapses against a black background.

Improving ALS research with pluripotent stem cell-derived models 

Discover new advancements in modeling amyotrophic lateral sclerosis.

Automating 3D cell selection

Discover precise automated tools for organoid and spheroid handling. 
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue